Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing...
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing...
Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas Partnership brings real-time site...
Black Book Research Flash Survey of 126 Healthcare Investors Pinpoints Largely Untapped, High-Conviction Markets for Startups, Scaleups, and Strategic Expansion...
Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287,...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive...
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial...
Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi®...
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight...
The untold truth? Rescheduling may not save the cannabis industry-it could divide it.Past IRS 280E tax liabilities won't vanish-some companies...
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort...
Clinically studied, drug-free postbiotic now available nationally SHELTON, Conn., Aug. 14, 2025 /PRNewswire/ -- Parents across the U.S. now have...
STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the...
Built to Connect Patients and Providers, the HFSA Database is Now Open for Searching and Submissions WASHINGTON, Aug. 14, 2025...
NEW CASTLE, Del., Aug. 14, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, today announced the close...
- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14,...
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell...
Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300...
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately...
Live video webcast on Wednesday, August 20th at 2:40 PM ETOCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its...